33141-66-1

Usage

Uses

Used in Organic Synthesis:
ETHYL 4-BROMO-3-HYDROXYBENZOATE is used as a building block in organic synthesis for the creation of a variety of pharmaceuticals and fine chemicals. Its unique structure allows for the development of complex organic molecules that can be utilized in various applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, ETHYL 4-BROMO-3-HYDROXYBENZOATE is employed as a key intermediate in the synthesis of new drug candidates. Its presence in the molecular structure can influence the pharmacological properties of the final product, making it a valuable component in drug discovery and development.
Used as a Reagent in the Preparation of Esters:
ETHYL 4-BROMO-3-HYDROXYBENZOATE is utilized as a reagent in the preparation of esters, which are important in the synthesis of various organic compounds. Its reactivity and functional groups make it suitable for esterification reactions, contributing to the formation of esters with specific properties.
Used in the Preparation of Other Organic Compounds:
Beyond its role in ester synthesis, ETHYL 4-BROMO-3-HYDROXYBENZOATE is also used in the preparation of other organic compounds. Its versatility in organic reactions makes it a valuable tool in the synthesis of a wide range of chemical products.

Upstream product

• 64-17-5 ethanol 
• 14348-38-0 4-bromo-3-hydroxybenzoic acid 
• 99-06-9 3-Carboxyphenol 
• 7781-98-8 ethyl-3-hydroxybenzoate 

Downstream Products

• 540779-35-9 ethyl 4-bromo-3-benzyloxybenzoate 
• 908247-81-4 Ethyl 3-(2-hydroxy-2-methylpropoxy)-4-bromobenzoate 
• 220380-11-0 ethyl-4-bromo-3-ethoxybenzoate 
• 908247-86-9 ethyl 4-bromo-3-cyclopropylmethoxy-benzoate 

Relevant academic research and scientific papers

Total Synthesis of Benzofuran-Based Aspergillusene B via Halogenative Aromatization of Enones

A novel "non-aromatic pool" synthetic strategy for the synthesis of benzofuran-based natural products via oxidative haloaromatization of enones is reported. This approach is successfully applied in the first total synthesis of the natural product aspergil

Antagonist analogue of 6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-2- naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest

The retinoid 6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-2- naphthalenecarboxylic acid (AHPN) and its active analogues induce cell-cycle arrest and programmed cell death (apoptosis) in cancer cells independently of retinoic acid receptor (RAR) interaction. Its analogue, (E)-4-[3′-(1- adamantyl)-4′-hydroxyphenyl]-3-(3′-acetamidopropyloxy)cinnamic acid (3-A-AHPC) selectively antagonized cell apoptotic events (TR3/nur77/NGFI-B expression and nuclear-to-mitochondrial translocation) but not the proliferative events (cell-cycle arrest and p21WAF1/CIP1 expression) induced by proapoptotic AHPN and its analogues. The syntheses of 3-A-AHPC and proapoptotic (E)-6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-5- chloronaphthalenecarboxylic acid (5-Cl-AHPN) are described. Computational studies on AHPN, AHPC, and three substituted analogues (5-Cl-AHPN, 3-Cl-AHPC, and 3-A-AHPC) suggested reasons for their diametric effects on RAR activation. Density functional theory studies indicated that the 1-adamantyl (1-Ad) groups of the AHPN and AHPC configurations assumed positions that were nearly planar with the aromatic rings of their polar termini. In contrast, in the configurations of the substituted analogues having chloro and 3-acetamidopropyloxy groups, rather than a hydrogen, ortho to the diaryl bonds, the diaryl bond torsion angles increased so that the 1-Ad groups were oriented out of this plane. Docking and molecular dynamics of AHPN, AHPC, and these substituted analogues in the RARγ ligand-binding domain illustrated how specific substituents on the AHPN and AHPC scaffolds modulated the positions and dynamics of the 1-Ad groups. As a result, the position of RARγ helix H12 in forming the coactivator-binding site was impacted in a manner consistent with the experimental effect of each analogue on RARγ transcriptional activation.

BIPHENYL CARBOXYLIC AMIDE P38 KINASE INHIBITORS

Compounds of formula (I) or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.